No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.

abstract：:SUMO (small ubiquitin-related modifier) represents a class of ubiquitin-like proteins that is conjugated, like ubiquitin, by a set of enzymes to cellular regulatory proteins, including oncogenes and tumor suppressor genes, that play key roles in the control of cell growth, differentiation and apoptosis. SUMO conjugati...

journal_title：Cancer biology & therapy

authors： Alarcon-Vargas D,Ronai Z

更新日期：2002-05-01 00:00:00

abstract：:Onconase (Onc), a ribonuclease from oocytes or early embryos of Northern Leopard frog (Rana pipiens), is cytostatic and cytotoxic to a variety of tumor lines in vitro, inhibits growth of tumors in animal in vivo models and is currently in Phase IIIb clinical trials for malignant mesothelioma where it displays antitumo...

journal_title：Cancer biology & therapy

authors： Ita M,Halicka HD,Tanaka T,Kurose A,Ardelt B,Shogen K,Darzynkiewicz Z

更新日期：2008-07-01 00:00:00

abstract：BACKGROUND AND AIM:H. pylori interacts with gastric epithelial cells, which may activate signaling pathways important for gastric cancer invasion. Ezrin, a membrane cytoskeletal crosslinker protein, is well documented to regulate cell adhesion and cell motility. The aim of the present study was to determine whether ezr...

journal_title：Cancer biology & therapy

authors： Fan LL,Chen DF,Lan CH,Liu KY,Fang DC

更新日期：2011-04-15 00:00:00

abstract：OBJECTIVES:To determine the effects of adenovirus-mediated transfer of p14(ARF) and p16(INK4a) on growth and apoptosis of human pancreatic carcinoma cell lines. RESULTS:Pancreatic carcinoma cell lines, PC-7, PANC-1 and MIA PaCa-2 (p14(ARF)-/- and p16(INK4a)-/-), were used. PC-7 (p53 wt) and MIA PaCa-2 (p53 mt) cells i...

journal_title：Cancer biology & therapy

authors： Chen F,Li Y,Lu Z,Gao J,Chen J

更新日期：2005-12-01 00:00:00

abstract：:Rhabdomyosarcoma (RMS) is an aggressive childhood sarcoma with two distinct subtypes, embryonal (ERMS) and alveolar (ARMS) histologies. More effective treatment is needed to improve outcomes, beyond conventional cytotoxic chemotherapy. The pan-histone deacetylase inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), has ...

journal_title：Cancer biology & therapy

authors： Ghayad SE,Rammal G,Sarkis O,Basma H,Ghamloush F,Fahs A,Karam M,Harajli M,Rabeh W,Mouawad JE,Zalzali H,Saab R

更新日期：2019-01-01 00:00:00

abstract：:We studied the mechanism of the cytotoxic activity of BZL101, an aqueous extract from the herb Scutellaria barbata D. Don, which is currently in phase II clinical trial in patients with advanced breast cancer. The phase I trial showed favorable toxicity profile and promising efficacy. We report here that BZL101 induce...

journal_title：Cancer biology & therapy

authors： Fong S,Shoemaker M,Cadaoas J,Lo A,Liao W,Tagliaferri M,Cohen I,Shtivelman E

更新日期：2008-04-01 00:00:00

abstract：:Current risk stratification using clinical and pathological parameters in patients with urothelial carcinoma of the bladder (UCB) is insufficient. Additional information on the tumor biology can be derived from molecular biomarkers assessed in surgical UCB specimens and the predictive accuracy of oncologic end points ...

journal_title：Cancer biology & therapy

authors： Bolenz C,Lotan Y

更新日期：2010-09-01 00:00:00

abstract：:Telomerase is the ribonucleoprotein that enables cancer and stem cells to maintain their telomeres, resulting in unlimited proliferative potential. The catalytic component of telomerase in humans, hTERT, is upregulated in nearly 90% of all cancers, making it the most widely expressed marker of malignancy. With the exc...

journal_title：Cancer biology & therapy

authors： Nguyen B,Elmore LW,Holt SE

更新日期：2003-03-01 00:00:00

abstract：PURPOSE:The sensitivity of lung cancer to gefitinib has been found to be associated with mutations at the tyrosine kinase domain of epidermal growth factor receptor (EGFR), yet similar observations are not available in other solid tumors. We recently identified mutations in the EGFR kinase domain in primary esophageal ...

journal_title：Cancer biology & therapy

authors： Guo M,Liu S,Herman JG,Zhuang H,Lu F

更新日期：2006-02-01 00:00:00

abstract：:The clinical use of EGFR-targeted therapy, in triple negative breast cancer patients, has been limited by the development of resistance to these drugs. Although activated signaling molecules contribute to this process, the molecular mechanisms remain relatively unknown. We have previously reported that the small GTPas...

journal_title：Cancer biology & therapy

authors： Haines E,Schlienger S,Claing A

更新日期：2015-01-01 00:00:00

abstract：:Hypoxia is an important phenomenon in the tumor microenvironment. Hypoxic tumors are more aggressive and resistant to anti-neoplastic treatments. HIF-1alpha plays a major role in the response of tumors to hypoxia, and it is mainly responsible for the "angiogenic switch". HIF-1alpha contributes to tumor aggressiveness,...

journal_title：Cancer biology & therapy

authors： Diaz-Gonzalez JA,Russell J,Rouzaut A,Gil-Bazo I,Montuenga L

更新日期：2005-10-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC), characterized by a high rate of metastasis and recurrence after surgery, is caused by malignant proliferation of hepatocytes with epigenetic and/or genetic mutations. In particular, abnormal activation of the hepatocyte growth factor (HGF)-/c-mesenchymal-epithelial transition receptor (...

journal_title：Cancer biology & therapy

authors： Zhao M,Wang Y,Liu Y,Zhang W,Liu Y,Yang X,Cao Y,Wang S

更新日期：2019-01-01 00:00:00

abstract：:Epithelial-mesenchymal transition (EMT) is a critical early event in tumorigenesis. The contribution of heparan sulfate (HS) to EMT has not been fully elucidated. HS D-glucosaminyl 3-O-sulfotransferase-3B1 (3-OST-3B1) participates in the final step of HS fine structure biosynthesis, whose involvement in cancer has yet...

journal_title：Cancer biology & therapy

authors： Song K,Li Q,Jiang ZZ,Guo CW,Li P

更新日期：2011-09-01 00:00:00

abstract：:B-cell chronic lymphocytic leukemia (CLL) is caused by the abnormal accumulation of non-functional B-cells in peripheral blood and bone marrow. However, the precise aetiology and mechanism of the disease are unclear. Recently, progress has been made in the identification of both the genetic deficiencies and environmen...

journal_title：Cancer biology & therapy

authors： Chen J,McMillan NA

更新日期：2008-02-01 00:00:00

abstract：:The pathogenesis of sporadic colorectal cancer involves distinct pathways, with characteristic genomic alterations. The first pathway, chromosome instability (CIN), is driven by APC mutations and is typified by Kras mutations, p53 mutation/loss of heterozygosity, and deletions at chromosome 18q. The second pathway is ...

journal_title：Cancer biology & therapy

authors： Ye Y,Madison B,Wu X,Rustgi AK

更新日期：2012-12-01 00:00:00

abstract：:Ecto-5'-nucleotidase (CD73) was overexpressed in malignancies of epithelial origin and was involved in a variety of cellular processes such as cytoprotection and anti-inflammation. In the present study, human mammary T-47D cells were transfected with pcDNA-NT5E to establish a CD73 overexpressed cell model. Short small...

journal_title：Cancer biology & therapy

authors： Zhou P,Zhi X,Zhou T,Chen S,Li X,Wang L,Yin L,Shao Z,Ou Z

更新日期：2007-03-01 00:00:00

abstract：:Endostatin can inhibit tumor growth by blocking angiogenesis, whereas tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) may function as a soluble cytokine to selectively kill cancer cells without toxicity to most normal cells. To establish the combined anti-tumor therapeutic effect of endostatin and solu...

journal_title：Cancer biology & therapy

authors： Zhang Y,Qu ZH,Cui M,Guo C,Zhang XM,Ma CH,Sun WS

更新日期：2009-03-01 00:00:00

abstract：:Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial-growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based co...

journal_title：Cancer biology & therapy

authors： Correale P,Botta C,Basile A,Pagliuchi M,Licchetta A,Martellucci I,Bestoso E,Apollinari S,Addeo R,Misso G,Romano O,Abbruzzese A,Lamberti M,Luzzi L,Gotti G,Rotundo MS,Caraglia M,Tagliaferri P

更新日期：2011-07-15 00:00:00

abstract：:Metastatic cervical cancer remains a clinical problem. The development of more efficient treatment modalities and the optimal use of chemo- and radiotherapy require better understanding of their impact on regulation of cell survival and apoptosis, but the issue is insufficiently explored. Human papillomavirus (HPV) E6...

journal_title：Cancer biology & therapy

authors： Koivusalo R,Hietanen S

更新日期：2004-11-01 00:00:00

abstract：INTRODUCTION:Malignant cells are capable of an unlimited number of cell divisions, either through production of telomerase, or through the alternate lengthening of telomere (ALT) mechanism. Yeast cells with genomic instability have been shown to survive in the absence of telomerase by increased recombination events. We...

journal_title：Cancer biology & therapy

authors： Landen CN,Klingelhutz A,Coffin JE,Sorosky JI,Sood AK

更新日期：2004-12-01 00:00:00

abstract：:Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) registered for treating head and neck tumours. The present study was designed to evaluate the systemic and skin toxicity of chronic intravenous administration of the h-R3 in a relevant species demonstrated by comparing th...

journal_title：Cancer biology & therapy

authors： Arteaga ME,Ledón N,Casacó A,Pardo B,García M,Boleda M,Viña L,Orphee R,Hernández O,González C,Fuentes D,Rodríguez V,Charro L,Baro F,Macías A,Pérez A,Morales Y,Subirós N,González B,Ramos M,Rodriquez L,Ballester-La

更新日期：2007-09-01 00:00:00

abstract：:Our previous studies have demonstrated that atorvastatin induces autophagy in the androgen receptor negative prostate cancer PC3 cells through inhibition of geranylgeranyl biosynthesis [Parikh et al., Prostate. 70(9): 971-981 (2010)]. This study attempts to elucidate the molecular mechanism underlying atorvastatin-ind...

journal_title：Cancer biology & therapy

authors： Toepfer N,Childress C,Parikh A,Rukstalis D,Yang W

更新日期：2011-10-15 00:00:00

abstract：:As a kinase at the crossroads of numerous metabolic and cell growth signaling pathways, glycogen synthase kinase-3 beta (GSK-3β) is a highly desirable therapeutic target in cancer. Despite its involvement in pathways associated with the pathogenesis of several malignancies, no selective GSK-3β inhibitor has been appro...

journal_title：Cancer biology & therapy

authors： Sahin I,Eturi A,De Souza A,Pamarthy S,Tavora F,Giles FJ,Carneiro BA

更新日期：2019-01-01 00:00:00

abstract：:The present studies sought to further understand how the anti-folate pemetrexed and the multi-kinase inhibitor sorafenib interact to kill tumor cells. Sorafenib activated SRC, and via SRC the drug combination activated ERK1/2. Expression of dominant negative SRC or dominant negative MEK1 abolished drug-induced ERK1/2 ...

journal_title：Cancer biology & therapy

authors： Bareford MD,Hamed HA,Allegood J,Cruickshanks N,Poklepovic A,Park MA,Ogretmen B,Spiegel S,Grant S,Dent P

更新日期：2012-07-01 00:00:00

abstract：:One of the most active fields in cancer immunotherapy is the study of bispecific antibodies, which engage immune cells to kill cancer cells. However, a variety of issues are associated with most of current bispecific antibody formats. In this study, we present a novel bispecific antibody, BiSS (Bispecific antibody wit...

journal_title：Cancer biology & therapy

authors： Dong B,Zhou C,He P,Li J,Chen S,Miao J,Li Q,Wang Z

更新日期：2016-04-02 00:00:00

abstract：:Deregulated metabolism is gaining recognition as a hallmark of cancer cells, and is being explored for therapeutic potential. The Warburg effect is a metabolic phenotype that occurs in 90% of tumors, where glycolysis is favored despite the presence of oxygen. Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase (P...

journal_title：Cancer biology & therapy

authors： Gang BP,Dilda PJ,Hogg PJ,Blackburn AC

更新日期：2014-01-01 00:00:00

abstract：:Objective: Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated an unprecedented therapeutic efficacy in hematological malignancies; however, its effectiveness in solid tumors remains elusive. In order to enable CAR-T cells more effective to solid tumors, a inverted chimeric cytokine receptor (ICR) was de...

journal_title：Cancer biology & therapy

authors： Weimin S,Abula A,Qianghong D,Wenguang W

更新日期：2020-06-02 00:00:00

abstract：:Krüppel-Like Factor 4 (KLF4) functions as a tumor suppressor in some cancers, but its molecular mechanism is not clear. Our recent study also showed that the expression of KLF4 is dramatically reduced in primary lung cancer tissues. To investigate the possible role of KLF4 in lung cancer, we stably transfected KLF4 in...

journal_title：Cancer biology & therapy

authors： Zhou Y,Hofstetter WL,He Y,Hu W,Pataer A,Wang L,Wang J,Zhou Y,Yu L,Fang B,Swisher SG

更新日期：2010-04-01 00:00:00

abstract：:Although most researchers in biology tend to focus on very specific issues and questions about their preferred gene or pathway, sometimes we face situations in which nature presents us with a remarkable example of a gene with multiple functions. Since the discovery of the early growth response 1 (EGR1) gene in the mid...

journal_title：Cancer biology & therapy

authors： DeLigio JT,Zorio DA

更新日期：2009-10-01 00:00:00

abstract：:CP-31398, a styrylquinazoline, emerged from a screen for therapeutic agents that restore a wild-type DNA-binding conformation of mutant p53 to suppress tumors in-vivo (Science 286, 2507, 1999). We investigated the growth inhibitory mechanism of CP-31398 using nine human cancer cell lines containing wild-type, mutant o...

journal_title：Cancer biology & therapy

authors： Takimoto R,Wang W,Dicker DT,Rastinejad F,Lyssikatos J,el-Deiry WS

更新日期：2002-01-01 00:00:00